Key Takeaways
- Kastus Technologies, a Dublin-based startup, is revolutionizing biotech with its advanced antimicrobial surface coatings.
- Its technology is proven to kill >99% of harmful bacteria, viruses, fungi, and antibiotic-resistant superbugs, including the coronavirus.
- Investments and EU funding have made it possible for Kastus to contribute substantially to businesses reopening safely amidst the Covid-19 pandemic.
- Kastus’ innovative approach and its future potential mark it as a standout player in the bioinformatics and biotechnology industries.
Introduction
Could surface coatings be the key to combatting superbugs? Dublin-based startup, Kastus Technologies, believes so. The company specializes in creating antimicrobial surface coatings, providing a potentially game-changing answer to a grave health issue global governments and the healthcare sector have long struggled with. This is the alarming increase in antibiotic-resistant infections caused by bacteria and fungus surviving on surfaces and within indoor environments.
With over a decade of research and development behind it, Kastus was formally founded in 2014 by John Browne. From small beginnings, Kastus has grown rapidly not just in Ireland but globally, quickly establishing itself as a pioneering force in its field.
Differentiators
Kastus Technologies prides itself on its patented surface technology. Their products are VRSA and ISO validated, and have been proven to destroy more than 99% of harmful bacteria, viruses, fungi, and antibiotic-resistant superbugs, making it particularly useful for products inclusive of glass and ceramics. Most notably, independent ISO tests have shown that Kastus is proven to kill greater than 99% of human coronavirus.
In 2020, amidst the worldwide pandemic, Kastus stepped up, offering businesses an effective solution to reopen safely from lockdown. By launching a unique and easy-to-install product – the Antiviral and Antimicrobial screen protectors – Kastus effectively managed to bridge advanced technology with user-friendly practicality.
Conclusion
The future holds exciting prospects for Kastus and the general biotech industry. Kastus’ recent receipt of EU funding for developing an innovative business solution underlines its promising potential and influential role in shaping the future of the industry. It will be interesting to see how Kastus navigates future challenges and opportunities in an industry characterized by continually evolving tech and health landscapes.
You can follow Kastus and its journey towards revolutionizing biotech on its website (www.kastus.com) and social media platforms: Twitter (https://twitter.com/Kastus), Facebook (https://www.facebook.com/KastusTechnologies), and LinkedIn (https://www.linkedin.com/company/kastus).
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
